These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31222627)

  • 1. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
    Yilmaz M; Daver N
    Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
    Bohl SR; Bullinger L; Rücker FG
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel therapies in AML and their resistance mechanisms].
    Takahashi K
    Rinsho Ketsueki; 2022; 63(9):1052-1057. PubMed ID: 36198529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapies for acute myeloid leukemia.
    Stein EM
    Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
    Hauge M; Bruserud Ø; Hatfield KJ
    Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
    Yang J; Schiffer CA
    Expert Rev Hematol; 2012 Aug; 5(4):395-407. PubMed ID: 22992234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The most novel of the novel agents for acute myeloid leukemia.
    Perl AE
    Curr Opin Hematol; 2018 Mar; 25(2):81-89. PubMed ID: 29278535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in molecularly targeted therapies for acute myeloid leukemia].
    Tomita A
    Rinsho Ketsueki; 2015 Feb; 56(2):130-8. PubMed ID: 25765792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging therapies for acute myeloid leukaemia.
    Davis JR; Benjamin DJ; Jonas BA
    J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.